Chemical Nameamisulpride
Dosage FormInjection (intravenous; 5 mg/2 mL, 10 mg/4 mL)
Drug ClassDopamine-2 antagonists
CompanyAcacia Pharma
Approval Year2020


  • Indicated in adults for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class.
  • Indicated in adults for treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.
Document TitleYearSource
Barhemsys (amisulpride) Prescribing Information.2022Acacia Pharma Inc. Indianapolis, IN
Drug updated on 12/1/2022

More on this drug: Clinical Trials